Two receptors, one molecule
Tirzepatide is a single peptide that engages two related gut-hormone receptors. GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) are both incretins — hormones released from the small intestine after a meal that amplify insulin secretion in proportion to glucose load[14].
In pancreatic beta cells, activating both receptors at once produces more glucose-dependent insulin release than activating GLP-1 alone, while also suppressing glucagon. In the hypothalamus, the same receptors are involved in appetite regulation, which is part of why patients eat less. Tirzepatide also slows gastric emptying, contributing to satiety and reducing post-prandial glucose excursions[14].
Receptor-pharmacology work has shown that tirzepatide is what's called a biased agonist at the GLP-1 receptor: it favors cyclic-AMP (cAMP) signaling over beta-arrestin recruitment, with reduced receptor internalization compared with native GLP-1[14]. At the GIP receptor it is a full, balanced agonist. In primary human islets, the bias enhanced insulin secretion. The clinical relevance of these intracellular fingerprints is still being worked out, but the practical effect is large — tirzepatide consistently outperformed selective GLP-1 therapy on both glycemic control and body weight in head-to-head studies[3].
Five-day half-life by design
A population pharmacokinetic model built from 5,798 participants across phase 1, 2, and 3 trials describes tirzepatide as a two-compartment system with first-order absorption[15]. Median time to peak concentration is 24 hours after a subcutaneous dose (range 8 to 72 hours). Absolute bioavailability is approximately 80%. The terminal elimination half-life is about five days, and steady state is reached after roughly four weekly doses[15].
Exposure is dose-proportional from 0.25 mg through 15 mg. The model found no covariate effects large enough to require dose adjustment for renal function (including end-stage renal disease), hepatic impairment, sex, race, or body weight[15]. The five-day half-life is what makes once-weekly dosing biologically reasonable: by the time the next injection is due, the previous one has not fully cleared, which is the basis for steady-state coverage.
| Parameter | Value | Note |
|---|---|---|
| Route | SC | Abdomen, thigh, or upper arm |
| Tmax | ~24 h | Range 8–72 h |
| Bioavailability (SC) | ~80% | Pop-PK estimate |
| Terminal half-life | ~5 d | Albumin binding via C20 fatty di-acid |
| Steady state | ~4 wk | 4 weekly doses |
| Dose-proportionality | 0.25–15 mg | Linear PK |
SURPASS — type 2 diabetes
The SURPASS program supported the May 2022 type 2 diabetes approval. Six phase 3 trials, each testing a different comparator or clinical setting.
SURPASS-1 (drug-naive)
Randomized drug-naive adults with type 2 diabetes to placebo or one of three tirzepatide doses (5, 10, 15 mg weekly) for 40 weeks. The 15 mg arm reduced HbA1c by 2.07 percentage points versus a 0.04 increase on placebo, with weight reduction up to 9.5 kg (about 11%)[2].
SURPASS-2 (head-to-head vs semaglutide)
Compared tirzepatide head-to-head with injectable semaglutide 1 mg in 1,879 adults on metformin. Over 40 weeks, all three tirzepatide doses produced superior HbA1c and weight reductions; 60% of the 15 mg arm achieved HbA1c at or below 6.5% with at least 10% weight loss, versus 22% with semaglutide[3].
SURPASS-2 head-to-head HbA1c reduction
SURPASS-3 (vs insulin degludec)
Measured tirzepatide against titrated basal insulin degludec over 52 weeks. HbA1c reductions ranged from 1.93 to 2.37 percentage points across the three tirzepatide doses versus 1.34 for degludec, and body weight dropped 7.5 to 12.9 kg with tirzepatide while rising 2.3 kg on insulin[4].
SURPASS-4 (CV-risk cohort)
Enrolled adults with type 2 diabetes and elevated cardiovascular risk and compared the three tirzepatide doses with titrated insulin glargine over 52 weeks. The 15 mg arm reduced HbA1c by 2.58 percentage points versus 1.44 for glargine; the four-component MACE hazard ratio was 0.74, with no signal of increased cardiovascular risk[5].
SURPASS-5 (add-on to basal insulin)
Added tirzepatide to basal insulin glargine. Over 40 weeks, the 15 mg add-on reduced HbA1c by 2.11 percentage points versus 0.86 for placebo, with lower hypoglycemia rates than expected at higher tirzepatide doses[6].
SURMOUNT — obesity
SURMOUNT is the obesity counterpart to SURPASS. Four trials supported the November 2023 chronic weight management approval.
SURMOUNT mean body-weight reduction by dose
SURMOUNT-1 (obesity without T2DM)
The headline trial. In 2,539 adults with obesity (BMI at least 30) or overweight (BMI at least 27 with a comorbidity), without type 2 diabetes, 72 weeks of tirzepatide produced mean body weight reductions of 16.0% (5 mg), 21.4% (10 mg), and 22.5% (15 mg), versus 2.4% on placebo[1]. At the 15 mg dose, 91% of participants achieved at least 5% weight loss.
SURMOUNT-2 (obesity with T2DM)
Asked whether the same effect held in adults who also had type 2 diabetes (weight loss is typically blunted in this population). It did, though somewhat attenuated: 15.7% weight loss on 15 mg and 13.4% on 10 mg, versus 3.3% on placebo[7].
SURMOUNT-3 (after lifestyle lead-in)
Added a 12-week intensive lifestyle lead-in before randomization. After the lead-in (which produced about 6% weight loss for everyone), 72 weeks of tirzepatide added a further 18.4% reduction versus 2.5% with placebo — a roughly 21 percentage-point difference[8]. The trial demonstrates that tirzepatide adds incremental benefit on top of a structured lifestyle program rather than substituting for it.
SURMOUNT-4 (withdrawal)
Addressed what happens when treatment stops. After 36 weeks of open-label tirzepatide (during which participants lost about 21% of body weight), they were randomized to continue tirzepatide or switch to placebo for 52 weeks. Continued treatment maintained 25.3% total weight loss at 88 weeks; withdrawal to placebo caused regain of 14.0 percentage points[9]. The trial establishes tirzepatide-supported weight loss as a chronic-treatment paradigm rather than a course of therapy.
SURMOUNT-OSA, SUMMIT, SYNERGY-NASH — beyond glycemia and weight
Three trials published in 2024 extended the program into adjacent conditions where obesity is mechanistic.
SURMOUNT-OSA (sleep apnea)
Randomized adults with moderate-to-severe obstructive sleep apnea and obesity to maximum-tolerated tirzepatide (10 or 15 mg) or placebo for 52 weeks. The apnea-hypopnea index — the number of breathing pauses per hour of sleep — dropped by 25 to 29 events per hour on tirzepatide versus 5 to 6 on placebo, a reduction of up to 62.8% from baseline[10]. The trial was the basis for the December 20, 2024 FDA approval for OSA in adults with obesity.
SURMOUNT-OSA mean AHI reduction
SUMMIT (HFpEF)
Studied heart failure with preserved ejection fraction (HFpEF) in adults with obesity. Over up to three years of follow-up, tirzepatide reduced a composite of cardiovascular death or worsening heart failure events with a hazard ratio of 0.62 and improved both Kansas City Cardiomyopathy Questionnaire scores and six-minute walk distance[11].
SYNERGY-NASH (MASH)
Enrolled adults with metabolic-dysfunction-associated steatohepatitis (MASH — the current name for what was called NASH) and moderate-to-severe liver fibrosis. After 52 weeks of treatment, histology-confirmed resolution of steatohepatitis without worsening fibrosis was 51.8% at 5 mg, 62.8% at 10 mg, and 73.3% at 15 mg, versus 13.2% on placebo[12]. Higher doses also showed a signal for fibrosis improvement.
SURPASS-CVOT and the prediabetes extension
Two large 2025 publications round out the current picture.
SURPASS-CVOT
The dedicated cardiovascular outcomes trial: adults with type 2 diabetes and cardiovascular risk randomized to maximum-tolerated tirzepatide or dulaglutide 1.5 mg weekly, with a median follow-up of about four years. The primary composite of cardiovascular death, myocardial infarction, or stroke occurred in 12.2% of the tirzepatide group versus 13.1% of the dulaglutide group — meeting non-inferiority but not superiority (P=0.09). All-cause mortality was 16% lower in relative terms with tirzepatide, and blood pressure and lipid improvements were larger[13].
SURPASS-CVOT 3-point MACE event rate
SURMOUNT-1 176-week extension (prediabetes)
Followed adults with obesity and prediabetes for three years. Progression to type 2 diabetes occurred in 1.3% of tirzepatide-treated participants versus 13.3% on placebo — a 94% relative reduction — while weight loss was largely sustained at 176 weeks[19]. The trial is the strongest evidence to date that pharmacologic weight management can substantially delay or prevent type 2 diabetes in a high-risk population.
A pooled SURPASS analysis also reported systolic blood pressure reductions of 4 to 6 mmHg across SURPASS-1 through -5, with roughly half of the effect mediated by weight loss[18].